Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

Biosimilar Competition Linked to Lower Out-of-Pocket Costs for Medicare Patients

January 21st 2026

By Skylar Jeremias

Biosimilar competition significantly reduces out-of-pocket costs for Medicare patients, enhancing affordability for biologic therapies and improving access.

Perceptions Still Play a Central Role in Biosimilar Insulin Switching

January 20th 2026

By Skylar Jeremias

Explore the complexities of insulin biosimilars, their safety, and the impact on diabetes management in global health systems.

Trial Data Support Equivalence of Denosumab Biosimilar in Postmenopausal Osteoporosis

January 16th 2026

By Skylar Jeremias

Denosumab biosimilars enhance treatment access for postmenopausal osteoporosis, demonstrating equivalent efficacy and safety to reference products in recent trials.

What Australia’s Experience Reveals About Biosimilar Adoption and Pricing

January 15th 2026

By Skylar Jeremias

Australia's biosimilar adoption significantly reduces biologic medicine costs, enhancing access while maintaining utilization amid tighter health care budgets.

Eye on Pharma: Global Approvals, Launches, and Strategic Partnerships

January 12th 2026

By Skylar Jeremias

Real-World Study Finds Stable Vision After Switch to Ranibizumab Biosimilar

January 7th 2026

By Skylar Jeremias

Switching from aflibercept to ranibizumab biosimilars maintains stability in nAMD treatment, offering a cost-effective solution for long-term management.

Evidence Supports Safe, Effective Switching to Etanercept Biosimilars

January 6th 2026

By Skylar Jeremias

Explore the safety and efficacy of switching to etanercept biosimilars, backed by clinical trials and real-world evidence for chronic inflammatory diseases.

FDA Approves Amneal Denosumab Biosimilars, Capping Year of Market Expansion

January 6th 2026

By Skylar Jeremias

FDA approves new denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases while driving competition and cost savings.

Evidence Gaps Continue to Shape Biosimilar Adoption in Pediatric Care

January 5th 2026

By Skylar Jeremias

There are critical gaps in biosimilar adoption for pediatric patients, focusing on safety, regulatory challenges, and the need for more robust data.

Biosimilar Market Momentum: EU Approvals, Strategic Launches, and Major US Partnerships

January 2nd 2026

By Skylar Jeremias

Biosimilar partnerships and EU approvals surge, enhancing access to innovative treatments in immunology, oncology, and bone health markets.